Acorda Therapeutics announced that it has received notification from Nasdaq informing the company that as of June 20 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450. Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACOR: